These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 11594691)

  • 21. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.
    Yeh CT; Chien RN; Chu CM; Liaw YF
    Hepatology; 2000 Jun; 31(6):1318-26. PubMed ID: 10827158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy.
    Gwak GY; Huh W; Lee DH; Choi MS; Lee JH; Koh KC; Kim SJ; Joh JW; Oh HY
    Transplant Proc; 2007 Dec; 39(10):3121-6. PubMed ID: 18089336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Determination of the lamivudine-resistant mutants of hepatitis B virus].
    Gervain J; Papp I; Csöndes M; Nemesánszky E; Rácz I; Ribiczey P; Telegdy L; Tornai I; Weisz G
    Orv Hetil; 2003 Jun; 144(25):1251-6. PubMed ID: 12901182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.
    Lai CL; Dienstag J; Schiff E; Leung NW; Atkins M; Hunt C; Brown N; Woessner M; Boehme R; Condreay L
    Clin Infect Dis; 2003 Mar; 36(6):687-96. PubMed ID: 12627352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy changes of short-term lamivudine therapy for chronic hepatitis B with emergence of YMDD mutation].
    Deng H; Lv Y; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jun; 12(6):368-9. PubMed ID: 15225437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.
    Tsubota A; Arase Y; Suzuki F; Kobayashi M; Matsuda M; Sato J; Suzuki Y; Akuta N; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    J Med Virol; 2004 May; 73(1):7-12. PubMed ID: 15042641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine.
    Hatakeyama T; Noguchi C; Hiraga N; Mori N; Tsuge M; Imamura M; Takahashi S; Kawakami Y; Fujimoto Y; Ochi H; Abe H; Maekawa T; Kawakami H; Yatsuji H; Aisaka Y; Kohno H; Aimitsu S; Chayama K
    Hepatology; 2007 May; 45(5):1179-86. PubMed ID: 17465002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
    van der Eijk AA; Hansen BE; Niesters HG; Janssen HL; van de Ende M; Schalm SW; de Man RA
    J Viral Hepat; 2005 Jul; 12(4):364-72. PubMed ID: 15985006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants.
    Chen CH; Lee CM; Lu SN; Wang JH; Tung HD; Hung CH; Chen WJ; Changchien CS
    J Hepatol; 2004 Sep; 41(3):454-61. PubMed ID: 15336449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy.
    Di Marco V; Di Stefano R; Ferraro D; Almasio PL; Bonura C; Giglio M; Parisi P; Cappello M; Alaimo G; Craxì A
    Antivir Ther; 2005; 10(3):431-9. PubMed ID: 15918334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of HBV gene variations on disease development and antiviral therapy for patients with chronic hepatitis B.
    Chen JY; Wang LW; Sun XM; Gong ZJ
    Hepatobiliary Pancreat Dis Int; 2005 Aug; 4(3):393-7. PubMed ID: 16109523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical study of oligonucleotide microarray on monitoring the lamivudine-resistance mutations in hepatitis B virus].
    Song JW; Lin JS; Kong XJ; Liang KH
    Zhonghua Gan Zang Bing Za Zhi; 2003 Jun; 11(6):361-3. PubMed ID: 12837218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.
    Ben-Ari Z; Daudi N; Klein A; Sulkes J; Papo O; Mor E; Samra Z; Gadba R; Shouval D; Tur-Kaspa R
    Am J Gastroenterol; 2003 Jan; 98(1):151-9. PubMed ID: 12526951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
    Yen YH; Lu SN; Chen CH; Wang JH; Wu CM; Hung CH; Tseng PL; Hu TH; Changchien CS; Lee CM
    Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.
    Matsuda M; Suzuki F; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Satoh J; Kobayashi M; Ikeda K; Miyakawa Y; Kumada H
    J Med Virol; 2004 Oct; 74(2):361-6. PubMed ID: 15332287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic changes of hepatitis B virus polymerase gene including YMDD motif in lamivudine-treated patients with chronic hepatitis B.
    Feng B; Wei L; Chen M; Wang L
    Microbiol Res; 2008; 163(4):487-92. PubMed ID: 17317127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Relationship between hepatitis B virus YMDD mutation and serum viral DNA loadings].
    Kong LH; Gao SX; Gui YP; Liu WH
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Aug; 27(8):1262-3. PubMed ID: 17715043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical study of lamivudine and interferon combinate administration to inhibit hepatitis B virus replication].
    Song JW; Zhang G; Lin JG; Tang WX; Lin JS
    Zhonghua Gan Zang Bing Za Zhi; 2004 Oct; 12(10):593-6. PubMed ID: 15504288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.